Skip to content
Clinical Trials – home
Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 41

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Conjunctivitis allergic+1

Not yet recruiting

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Betula Pendula Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

COVID-19+1

Not yet recruiting

Effectiveness of mCOMBRIAX vaccine compared with high‑dose influenza vaccine and mRNA‑1273 in adults ≥65 years for prevention of influenza and COVID‑19

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years · Healthy volunteers
  • Substances:B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type)
  • Sponsor:Gentofte Hospital

Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone Metasulfobenzoate Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Adenocarcinoma gastric+3

Not yet recruiting

Study of immune response and biomarkers in patients with metastatic solid tumors treated with BMS-986340 and nivolumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bms-986340
  • Sponsor:Humanitas Mirasole S.p.A.

Non-small cell lung cancer+1

Not yet recruiting

Phase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Rhinitis

Not yet recruiting

Randomized study of ketotifen nasal spray (0.025% and 0.050%) versus sodium cromoglicate nasal spray in patients with rhinitis

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Cromoglicate

Malignant pleural effusion

Not yet recruiting

Effect of Intrathoracic Aerosol Cisplatin and Doxorubicin on Malignant Pleural Effusion in Patients with Unresectable Pleural Carcinomatosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hospices Civils De Lyon

COVID-19

Not yet recruiting

Study of nirmatrelvir and remdesivir to achieve viral clearance in immunocompromised patients with persistent COVID-19

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Goethe University Frankfurt

Pleural mesothelioma

Not yet recruiting

Reducing Toxicity of Dual PD‑1 and CTLA‑4 Checkpoint Therapy in Pleural Mesothelioma Patients with Ustekinumab (anti‑p40)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ustekinumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cystic fibrosis

Not yet recruiting

Effect of Stopping Long‑Term Azithromycin in Stable Non‑Cystic Fibrosis Bronchiectasis Patients: A Randomized Controlled Trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Centre Hospitalier Intercommunal Creteil

Lung neoplasm malignant

Not yet recruiting

Feasibility Study of Fluorescence Bronchoscopy Using bevacizumab-800CW in Patients with Suspected Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Universitair Medisch Centrum Groningen

Study of Cemiplimab, Platinum and Gemcitabine in Treatment‑Naïve Patients with Advanced Squamous Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cemiplimab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.